{
    "clinical_study": {
        "@rank": "56952", 
        "arm_group": {
            "arm_group_label": "AutoloGel", 
            "arm_group_type": "Experimental", 
            "description": "Subjects will be treated on average twice a week for the first 2 weeks, and then, once a week thereafter while under active treatment, but actual frequency of treatment will be determined by the treating physician.  All subjects will receive AutoloGel treatment."
        }, 
        "brief_summary": {
            "textblock": "The aim of this trial is to demonstrate the effectiveness of complete wound healing in a\n      prospective, open-label, case-matched cohort trial in which diabetic foot ulcers (DFU) will\n      be treated using AutoloGel and case-matched against a concurrent cohort of patients\n      receiving undefined Usual and Customary Care (UCC) as provided in up to 30 U.S. Wound\n      Registry Research Network (USWRRN) centers."
        }, 
        "brief_title": "Effectiveness of AutoloGel Therapy in Diabetic Foot Ulcers", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetic Foot Ulcers", 
        "condition_browse": {
            "mesh_term": [
                "Ulcer", 
                "Foot Ulcer", 
                "Diabetic Foot"
            ]
        }, 
        "detailed_description": {
            "textblock": "AutoloGel is a platelet-rich plasma gel used in the treatment of non-healing chronic wounds.\n      Prospective observational studies of the effectiveness of AutoloGel have demonstrated\n      promising results in regard to the healing of DFUs, including severe Wagner grade 3 and 4\n      ulcers. The aim of this trial is to demonstrate the effectiveness of complete wound healing\n      in a prospective, open-label, case-matched cohort trial in which diabetic foot ulcers will\n      be treated using AutoloGel to determine the time to heal at 12 weeks. Comparison will be\n      made with a case-matched concurrent cohort of patients receiving undefined Usual and\n      Customary Care (UCC)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Medicare/Medicaid eligible\n\n          2. \u226518 years of age\n\n          3. Type I or II diabetes requiring medical treatment as determined by the physician\n\n          4. The largest non-healing wound, if multiple wounds are present, or the single wound to\n             be treated (Index Ulcer) is a Wagner 1-5 DFU (see Appendix 9 for Wagner\n             Classification) that is located on the dorsal, plantar, medial, or lateral aspect of\n             the foot or heel (including all toe surfaces)\n\n          5. For subjects with potentially multiple eligible DFUs, the largest ulcer will be\n             selected There must be at least 4 cm between the Index Ulcer and other ulcers; if all\n             ulcers are closer than 4 cm, the subject should not be enrolled (screen failure)\n\n          6. Debrided ulcer size between 0.5 cm2 and 50 cm2\n\n          7. Demonstrated adequate offloading regimen\n\n          8. Duration \u2265 1 month at first visit\n\n          9. Subject must be willing to comply with the Protocol, which will be assessed by\n             enrolling clinician.\n\n        Exclusion Criteria:\n\n          1. Subjects known to be sensitive to AutoloGel components (calcium chloride, thrombin,\n             ascorbic acid) and/or materials of bovine origin\n\n          2. Presence of another wound that is concurrently treated and might interfere with\n             treatment of the index wound by AutoloGel (malignancy in nearby wound)\n\n          3. Ulcer not of DFU pathophysiology (e.g., venous, vasculitic, radiation, rheumatoid,\n             collagen vascular disease, pressure, or arterial etiology)\n\n          4. Any malignancy other than non-melanoma skin cancer\n\n          5. Subjects who are cognitively impaired and do not have a healthcare proxy\n\n          6. Serum albumin of less than 2.5 g/dL\n\n          7. Plasma Platelet count of less than 100 x 109/L\n\n          8. Hemoglobin of less than 10.5 g/dL\n\n          9. Subject has inadequate venous access for repeated blood draw required for AutoloGel\n             Administration."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "380", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01816633", 
            "org_study_id": "CM002"
        }, 
        "intervention": {
            "arm_group_label": "AutoloGel", 
            "description": "AutoloGel is a platelet-rich plasma (PRP) gel used in the treatment of non-healing chronic wounds. It will be administered twice weekly for 2 weeks then weekly", 
            "intervention_name": "AutoloGel", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "non healing wound", 
        "lastchanged_date": "December 2, 2013", 
        "location": [
            {
                "contact": {
                    "email": "rinoie@att.net", 
                    "last_name": "Sato Rinoie, DPM", 
                    "phone": "(626) 821 9323"
                }, 
                "facility": {
                    "address": {
                        "city": "Arcadia", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91007"
                    }
                }, 
                "investigator": {
                    "last_name": "Sato Rinoie, DPM", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "bmarcus@hyperbarxs.com", 
                    "last_name": "Belinda Marcus, MD", 
                    "phone": "770-771-6400"
                }, 
                "facility": {
                    "address": {
                        "city": "Cumming", 
                        "country": "United States", 
                        "state": "Georgia"
                    }, 
                    "name": "HyperBarxs at Northside Forsyth"
                }, 
                "investigator": {
                    "last_name": "Belinda Marcus, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Multi-Center, Prospective, Cohort Trial Comparing the Effectiveness of AutoloGel Therapy to Usual and Customary Care in All Wagner Grades of Diabetic Foot Ulcers", 
        "overall_contact": {
            "email": "jearabino@cytomedix.com", 
            "last_name": "Jackie Earabino, RN"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Germany: Federal Institute for Drugs and Medical Devices"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary objective of the trial is to determine the time to heal diabetic foot ulcers treated with Autologel and Standard of Care at 12 weeks DFUs. Comparison will be made with a concurrent cohort of case matched subjects", 
            "measure": "Time to heal", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01816633"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Frequency of ulcer recurrence defined as any new ulcer appearing after the index ulcer healed", 
                "measure": "Ulcer recurrence", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }, 
            {
                "description": "Frequency of lower extremity amputations; major/minor amputations will be tabulated but not tested.", 
                "measure": "Incidence of amputations", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }, 
            {
                "description": "Proportion of patients with completely healed diabetic foot ulcers", 
                "measure": "Proportion of completely healed ulcers", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "Change in mean W-QOL (Quality of life with Chronic Wounds) score between baseline and 12 weeks", 
                "measure": "W-QOL (Quality of life with Chronic Wounds) score", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "Frequency and severity of adverse events", 
                "measure": "Number of patients with adverse events as a measure of tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }
        ], 
        "source": "Cytomedix", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Cytomedix", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}